U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07816185) titled 'A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)' on Sept. 07.
Brief Summary: A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
Study Start Date: Aug. 31
Study Type: INTERVENTIONAL
Condition:
Pulmonary Hypertension
Interstitial Lung Disease
Vascular Diseases
Cardiovascular Diseases
Fibrosis
Intervention:
DRUG: Mosliciguat
Dose level 1, 2, or 3 for inhalation
DRUG: Placebo
Matching Placebo for inhalation
DEVICE: Dry Powder Inhaler
Administratio...